(Q36105050)

12 August 2017

1 reference

title

Tailor-made antibody therapeutics (English)

1 reference

12 August 2017

Partha S Chowdhury

1

1 reference

PubMed ID

15848071

12 August 2017

Herren Wu

series ordinal

2

1 reference

12 August 2017

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

36

1 reference

12 August 2017

1

1 reference

12 August 2017

11-24

1 reference

Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Single-chain antigen-binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

A recombinant immunotoxin containing a disulfide-stabilized Fv fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Making antibody fragments using phage display libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Construction and evolution of antibody-phage libraries by DNA shuffling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Improving antibody affinity by mimicking somatic hypermutation in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Ligand-assisted aggregation of proteins. Dimerization of serum amyloid P component by bivalent ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Generation and iterative affinity maturation of antibodies in vitro using hypermutating B-cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

AID-dependent somatic hypermutation occurs as a DNA single-strand event in the BL2 cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Amino acid differences in the N-terminus of C(H)2 influence the relative abilities of IgG2 and IgG3 to activate complement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Engineered antibodies with increased activity to recruit complement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Complement function in mAb-mediated cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Substrate-assisted catalysis: molecular basis and biological significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

"Diabodies": small bivalent and bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Remodeling domain interfaces to enhance heterodimer formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

An efficient route to the production of an IgG-like bispecific antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Bispecific antibodies targeting cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Di-diabody: a novel tetravalent bispecific antibody molecule by design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Increasing the serum persistence of an IgG fragment by random mutagenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Engineered human IgG antibodies with longer serum half-lives in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

PEGylated antibodies and antibody fragments for improved therapy: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Therapeutic antibody fragments with prolonged in vivo half-lives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Sterically stabilized liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.002

10.1016/J.YMETH.2005.01.002

7 January 2021

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15848071